| Drug Name |
Tucatinib |
| Drug ID |
BADD_D02603 |
| Description |
Tucatinbib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.[L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945] |
| Indications and Usage |
Tucatinib is indicated with trastuzumab and capecitabine for treatment of adults diagnosed with advanced unresectable or metastatic HER2-positive breast cancer. This includes patients with brain metastases and those who have received one or more prior anti-HER2-based regimens in the metastatic setting.[L12945] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EH03 |
| DrugBank ID |
DB11652
|
| KEGG ID |
D11141
|
| MeSH ID |
C000705452
|
| PubChem ID |
51039094
|
| TTD Drug ID |
D09GRX
|
| NDC Product Code |
11014-0476; 43265-7481; 43265-7480; 51144-002; 57572-0723; 51144-001 |
| UNII |
234248D0HH
|
| Synonyms |
tucatinib | irbinitinib | ONT-380 | tukysa | N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine | N6-(4,5-dihydro-4,4-dmethyl-2-oxazolyl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-A)pyridin-7-Yloxy)phenyl)-4,6-quinazolinediamine |
